Afrezza and Glycosylated haemoglobin increased - a phase IV clinical study of FDA data

Summary:

Glycosylated haemoglobin increased is reported as a side effect among people who take Afrezza (insulin recombinant human), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Metformin, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Glycosylated haemoglobin increased when taking Afrezza. It is created by eHealthMe based on reports of 1,137 people who have side effects when taking Afrezza from the FDA, and is updated regularly.

What is Afrezza?

Afrezza has active ingredients of insulin recombinant human. eHealthMe is studying from 1,138 Afrezza users. Check the latest studies of Afrezza.

What is Glycosylated haemoglobin increased?

Glycosylated haemoglobin increased is found to be associated with 936 drugs and 950 conditions by eHealthMe. Check the latest studies of Glycosylated haemoglobin increased.

On Jul, 11, 2026

1,137 people reported to have side effects when taking Afrezza.
Among them, 13 people (1.14%) have Glycosylated haemoglobin increased.

Could Afrezza cause Glycosylated haemoglobin increased?

Among these 13 people:

How long have people been on Afrezza when they have Glycosylated haemoglobin increased? *

What is the gender of people who have Glycosylated haemoglobin increased when taking Afrezza? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Glycosylated haemoglobin increased when taking Afrezza? *

What are other drugs people take besides Afrezza? *

What are other side effects people have besides Glycosylated haemoglobin increased? *

Blood Glucose Increased: 6 people, 46.15%
Drug Ineffective: 5 people, 38.46%
Blood Glucose Decreased: 3 people, 23.08%
The Flu (the flu is caused by an influenza virus): 2 people, 15.38%
Rhinorrhea (watery mucus discharge from the nose): 2 people, 15.38%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 2 people, 15.38%
Muscle Aches (muscle pain): 2 people, 15.38%
Joint Pain: 2 people, 15.38%
Cough: 2 people, 15.38%
Visual Impairment: 1 person, 7.69%

What are the existing conditions these people have? *

Type 2 Diabetes: 7 people, 53.85%
Diabetes: 3 people, 23.08%
Type 1 Diabetes: 2 people, 15.38%
Thyroid Diseases: 1 person, 7.69%
Cushing's Syndrome (obesity, a rounded face, increased fat): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Afrezza and have Glycosylated haemoglobin increased?

- Check whether Glycosylated haemoglobin increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afrezza:

Afrezza (1,138 reports)

Browse all side effects of Afrezza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glycosylated haemoglobin increased:

Glycosylated haemoglobin increased (936 drugs)

Browse all the conditions that are associated with Glycosylated haemoglobin increased:

Glycosylated haemoglobin increased (950 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin recombinant human (the active ingredients of Afrezza) and Afrezza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.